For research use only. Not for use in humans.
Catalog No.S3005 Synonyms: BRL-29060A, FG-7051
Molecular Weight(MW): 365.83
Paroxetine HCl is an antidepressant drug of the SSRI type.
Purity & Quality Control
Choose Selective AChR Inhibitors
|Description||Paroxetine HCl is an antidepressant drug of the SSRI type.|
Paroxetine apparently exerts their antidepressant activity by increasing the concentration of 5-HT in the extracellular compartment, thereby enhancing serotoninergic neurotransmission. Paroxetine (1-300 μM) results in a concentration-dependent reduction in the firing rate of DRN serotoninergic neurons with IC50 values of 1.4 μM in the ACSF superfusing brain stem slices.  Paroxetine is a highly potent inhibitor of desipramine hydroxylation, the inhibition constant (Ki) value of 2.0 mM indicated greater inhibiting potency than fluoxetine or norfluoxetine.  Paroxetine is shown to be a potent (Ki = 1.1 nM) and specific inhibitor of [3H]-5-hydroxytryptamine (5-HT) uptake into rat cortical and hypothalamic synaptosomes in vitro. Paroxetine demonstrates weak affinity for muscarinic receptors (Ki = 89 nM) but is at least 15 fold weaker than amitriptyline (Ki = 5.1 nM).  Paroxetine inactivates CYP2D6 via the formation of a metabolite intermediate complex. 
|In vivo||Paroxetine produces a dose-related inhibition of [3H]-5-HT uptake (ED50 = 1.9 mg/kg) into rat hypothalamic synaptosomes ex vivo with little effect on [3H]-l-noradrenaline (NA) uptake (ED50 greater than 30 mg/kg). Paroxetine (ED50 1-3 mg/kg PO) prevents the 5-HT depleting effect of p-chloroamphetamine (PCA) in rat brain, demonstrating 5-HT uptake blockade in vivo. |
-  Le Poul E, et al. Naunyn Schmiedebergs Arch Pharmacol, 1995, 352(2), 141-148.
-  von Moltke LL, et al. J Clin Psychopharmacol, 1995, 15(2), 125-131.
-  Thomas DR, et al. Psychopharmacology (Berl), 1987, 93(2), 193-200.
|In vitro||DMSO||73 mg/mL (199.54 mM)|
|Ethanol||35 mg/mL (95.67 mM)|
|Water||1 mg/mL (2.73 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03329573||Completed||Drug: Paroxetine IR tablets A|Drug: Paroxetine IR tablets B||Anxiety Disorders||GlaxoSmithKline||May 30 2018||Phase 1|
|NCT02932904||Completed||Drug: Vortioxetine|Drug: Paroxetine|Drug: Placebo||Healthy Volunteers||Takeda||November 21 2016||Phase 4|
|NCT02174822||Completed||Drug: AVP-786|Drug: Paroxetine|Drug: Duloxetine||Drug-drug Interaction||Avanir Pharmaceuticals||January 2014||Phase 1|
|NCT03254342||Recruiting||--||Major Depressive Disorder|Major Depressive Episode|Major Depressive Disorder Recurrent|Major Depression Mild|Major Depression Moderate|Major Depression Severe||Stanford University||August 6 2013||--|
|NCT01841502||Terminated||Drug: Paroxetine|Drug: telaprevir||Hepatitis C Infection|Depression||Radboud University|Janssen LP||May 2013||Phase 2|
|NCT01829919||Completed||Drug: Brisdelle (paroxetine mesylate)||Postmenopausal Symptoms||Noven Therapeutics||July 2011||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.